KMTS Stock Forecast & Price Target

Kestra Medical Techs is supported by strong commercial execution, with F1Q27 sales of $31.0M, up 60% year over year and about $2M above consensus, driven by share gains, new account activations, and a low-80s% in-network mix that improves conversion and reimbursement. Its ASSURE WCD is benefiting from a WCD market growing about 14% year over year, while management’s AI automation, territory expansion, and better revenue cycle management should support further penetration and operating leverage. Fundamentally, rising gross margin to 56.5%, a raised FY27 revenue guide to $141M, and total liquidity of roughly $320M highlight both improving unit economics and the financial capacity to keep scaling.

Kestra Medical Techs is a commercially early but still fragile business whose valuation rests on a rapid ramp that may not fully offset execution risk, reimbursement dependence, and balance-sheet constraints. Although quarterly revenue has almost doubled to $28.6M since the March 2025 IPO and ASSURE holds only about 15% unit share, the company still faces a difficult adoption model that depends on costly fittings, 90% payer coverage, and low-80s% in-network prescriptions versus ZOLL’s ~98%. Even with strong clinical data such as 6% false alarms and >23 hours/day wear time, the analyst’s negative outlook reflects the need for sustained profitability improvement, regulatory support, and broader market penetration before the commercial story becomes durable.